Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Joins GHIT Fund as 21st Funding Partner
October 16, 2018
- China Regulators Accept NDA for Fycompa
October 15, 2018
- Chugai Sues Daiichi Sankyo, Pfizer over Herceptin Biosimilars
October 15, 2018
- Oncodesign Strengthens Its Cooperation with Eisai
October 15, 2018
- Kyorin Begins Collaborative Research on Antibiotics with Microbial Chemistry Research Foundation
October 12, 2018
- Nippon Shinyaku to Expand Contract Manufacturing Biz with New Facility to Start Full Operation in Feb.
October 12, 2018
- Avastin Top-Seller in Japan for 2nd Straight Month in September: Encise Snapshot
October 11, 2018
- Perjeta Gets Japan OK as Neoadjuvant, Adjuvant Therapy for HER2 Breast Cancer
October 11, 2018
- Shonan iPark to Focus on Disease Prevention, 3 Other Areas, Aiming to House 200 Companies by FY2023
October 11, 2018
- Towa’s Allegra Generic Grabs Approval for Expanded Pediatric Use
October 11, 2018
- Opdivo/Yervoy Combo Gets 1st Line RCC Nod in South Korea
October 10, 2018
- Ethical Drug Sales Down 2.0% in August: Crecon
October 10, 2018
- Celgene’s CAR-T Therapy Earns Orphan Status in Japan
October 10, 2018
- Patient Enrollment Completed in Japan PIII Study of Diabetes Treatment Imeglimin: Poxel
October 10, 2018
- 3 Japan Major Pharmas to Launch 2nd Open Drug Reposition Program
October 10, 2018
- Funding Disclosures Reveal Changes in Money Flows; Biz Models, Pricing Reform Driving the Shift
October 9, 2018
- Osaka Univ. Spinout FunPep Raises 460 Million Yen
October 9, 2018
- Canada Approves Mitsubishi Tanabe’s ALS Med Radicava
October 9, 2018
- Belviq Reduces Risk of Progression to Type 2 Diabetes: Eisai
October 9, 2018
- Takeda Alumni Shareholders Send Open Letter Questioning Shire Buyout
October 9, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…